Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Symptomatic cryoglobulinemia.

A Dispenzieri1

  • 1Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Treating symptomatic cryoglobulinemia is complex due to its varied presentation and limited evidence-based therapies. Management strategies depend on cryoglobulinemia type and severity, with interferon-alpha as a key option for hepatitis C-associated cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024
Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023
Same author

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Blood cancer journal·2021
Same author

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.

Blood cancer journal·2021
Same author

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2021
Same author

Systemic amyloidosis from A (AA) to T (ATTR): a review.

Journal of internal medicine·2020
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Area of Science:

  • Rheumatology
  • Hematology
  • Immunology

Background:

  • Symptomatic cryoglobulinemia presents challenges due to multisystemic involvement, variable disease course, and limited randomized controlled trials.
  • Effective therapeutic options for cryoglobulinemia are scarce, necessitating careful management strategies based on disease type and severity.

Purpose of the Study:

  • To outline current treatment approaches for symptomatic cryoglobulinemia.
  • To provide guidance on managing different types and severities of cryoglobulinemia.
  • To highlight future directions in cryoglobulinemia therapy research.

Main Methods:

  • Review of existing literature and clinical guidelines for cryoglobulinemia treatment.
  • Categorization of treatment strategies based on cryoglobulinemia type (essential vs. secondary) and clinical presentation (mild, symptomatic, life-threatening).

Related Experiment Videos

  • Identification of first-line therapies and adjunctive treatments for specific cryoglobulinemia subtypes.

    • Main Results:

    • Mild, asymptomatic cryoglobulinemia warrants observation without systemic therapy.
    • Type I secondary cryoglobulinemia treatment should target the underlying lymphoproliferative disorder.
    • Essential type II or III cryoglobulinemia associated with hepatitis C may be treated with interferon-alpha, potentially with corticosteroids or plasmapheresis.
    • Life-threatening presentations require combined modality therapy including corticosteroids, plasmapheresis, or alkylating agents.

    Conclusions:

    • Treatment of symptomatic cryoglobulinemia requires a tailored approach based on disease classification and clinical severity.
    • Interferon-alpha is a recommended first-line therapy for hepatitis C-associated cryoglobulinemia.
    • Further research is needed to develop and systematically evaluate novel and existing therapies for cryoglobulinemia.